![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Institut Gustave Roussy |
Information provided by: | Institut Gustave Roussy |
ClinicalTrials.gov Identifier: | NCT00162721 |
This is a Phase III study about the effects of the addition of polychemotherapy to adjuvant radiotherapy in the treatment of non-metastatic uterine sarcomas.
Condition | Intervention | Phase |
Uterine Sarcoma |
Drug: doxorubicin, ifosfamide, cisplatin |
Phase III |
MedlinePlus related topics: | Soft Tissue Sarcoma |
ChemIDplus related topics: | Doxorubicin Doxorubicin hydrochloride Ifosfamide Cisplatin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas |
Estimated Enrollment: | 270 |
Study Start Date: | September 2001 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Patricia Pautier, Dr | 33 1 42 11 4340 | pautier@igr.fr |
Contact: Annie Rey | 33 1 42 11 4137 | rey@igr.fr |
France | |||||
Institut Gustave Roussy | Recruiting | ||||
Villejuif, France, 94800 | |||||
Contact: Patricia Pautier, Dr 33 1 42 11 4340 pautier@igr.fr |
Institut Gustave Roussy |
Principal Investigator: | Patricia Pautier, Dr | Institut Gustave Roussy |
Study ID Numbers: | SARC-GYN1 |
First Received: | September 9, 2005 |
Last Updated: | August 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00162721 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|
![]() |